Friday 6 November 2026 Export TGTX’s income statement to Excel — free account

TG Therapeutics, Inc.

TGTX Healthcare Biotechnology

TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.

Revenue: +70.3%
EPS: −73.7%
Free cash flow: +427.1%
Total debt: +204.2%

Quarter to June 2026, against a year earlier

Revenue growth 3 yrs

59.60 1.62 +2.79%

Follow TGTX

Alert me

Market cap: $8.9B
P/E: 19.1×
Fwd P/E: 62.4×
Dividend yield: —
F-score: 5/9
Altman Z: 6.29
Beneish M: 0.80
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

TG Therapeutics, Inc. 10-Q filed Aug 5, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed Aug 5, 2026 · accepted 5:01 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed May 6, 2026: no comparison — low extraction confidence